- 1692.706
- +14.602+0.87%
Unusual Options Activity: STE, VST and Others Attract Market Bets, STE V/OI Ratio Reaches 107.7
EST Apr 29th Closing Delivery - In the last three hours of trading, 10 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trend
Quest Diagnostics Shares Are Trading Higher. The FDA Reportedly Finalized Its Rules That Aim to Bring Lab-developed Tests in Line With How It Oversees Other Diagnostics.
Quest Diagnostics Shares Are Trading Higher. The FDA Reportedly Finalized Its Rules That Aim to Bring Lab-developed Tests in Line With How It Oversees Other Diagnostics.
The "highest Quality" Stocks Within Each Sector - GS
Form 144 | Quest Diagnostics(DGX.US) Officer Proposes to Sell 246.4K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 29, $Quest Diagnostics(DGX.US)$ Officer KUPPUSAMY KARTHIK intends to sell 1,760 shares of its common stock on Apr 29, with a total market value of approximately $246.4K.
Quest Diagnostics, LabCorp Climb Following FDA Testing Oversight Rule
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today
Icon (NASDAQ:ICLR) has outperformed the market over the past 5 years by 4.98% on an annualized basis producing an average annual return of 16.62%. Currently, Icon has a market capitalization of $25.57
Quest Diagnostics Up Over 5%, on Pace for Largest Percent Increase Since October 2022 -- Data Talk
Quest Diagnostics Incorporated (DGX) is currently at $141.24, up $6.99 or 5.2% --Would be highest close since Jan. 9, 2024, when it closed at $142.11 --On pace for largest percent increase since Oct
Laboratory Corporation of America on Pace for Largest Percent Increase Since November 2022 -- Data Talk
Laboratory Corporation of America Holdings (LH) is currently at $206.91, up $8.51 or 4.29% --On pace for largest percent increase since Nov. 10, 2022, when it rose 5.44% --Currently up two consecuti
Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With BEQVEZ.
Labcorp Shares Are Trading Higher After the Company Announced That the FDA Approved Its NABCyte Anti-AAVRh74var HB-FE Assay, a Companion Diagnostic, to Determine Patient Eligibility for Treatment With
Iterum Therapeutics Resubmits New Drug Application to U.S. FDA for Oral Sulopenem
FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene Therapy
FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved He
Labcorp Receives FDA Approval for First Companion Diagnostic for Use With Pfizer's Newly Approved Gene Therapy to Treat Patients With Hemophilia B
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA)...
With Rate Cuts Pushed Out, Goldman Looks at Quality Stocks
Investors are looking to quality stocks amid the prospect of delayed Fed rate cuts.
ICON Public Limited Company's (NASDAQ:ICLR) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 37.3x ICON Public Limited Company (NASDAQ:ICLR) may be sending very bearish signals at the moment, given that almost half of all companies in the United St
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 16x, you may consider Charles River Laboratories International, Inc. (NYSE:CRL) as a stock to potentially avoid with its 24.8x P/E ratio.
Analyst Ratings For Laboratory Corp
In the latest quarter, 5 analysts provided ratings for Laboratory Corp (NYSE:LH), showcasing a mix of bullish and bearish perspectives.The table below offers a condensed view of their recent ratings,
TD Cowen: Maintaining the Icon (ICLR.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $343.00 to $349.00.
TD Cowen: Maintaining the Icon (ICLR.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $343.00 to $349.00.
Icon Price Target Cut to $330.00/Share From $350.00 by Evercore ISI Group
Icon Price Target Cut to $330.00/Share From $350.00 by Evercore ISI Group
Truist Securities: Maintaining Laboratory Corp's (LH.US) rating, adjusted from buy to buy rating, and adjusted target price from $270.00 to $255.00.
Truist Securities: Maintaining Laboratory Corp's (LH.US) rating, adjusted from buy to buy rating, and adjusted target price from $270.00 to $255.00.
UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating
UBS Adjusts ICON Price Target to $380 From $368, Maintains Buy Rating.